Kornimate/medical-research-clean huggingface dataset:
diagnostic performance of arterial time for ct assessment of parietal enhancement defect for the diagnosis of ischemia in mechanical small bowel occlusions: a comparative study with portal time

Conditions: Bowel Obstruction Small

Summary: intestinal obstruction is a frequent cause of emergency room visits and represents about 4-7% of the causes of acute abdominal pain syndrome and up to 30% in adults over 60 years old. although 65 to 80% of patients are treated medically, small bowel obstruction remains a serious pathology, with a high mortality rate that can reach 25% in case of small bowel ischemia. it is necessary to systematically perform a ct scan in the initial workup of small bowel obstructions to confirm the diagnosis, identify the mechanism and detect signs of ischemia that would require emergency surgery. the best sign for the diagnosis of ischemia is the defect or asymmetry of parietal enhancement of the dilated small bowel. in the literature, this sign is described almost exclusively at portal time. in case of suspicion of mesenteric ischemia (another serious pathology affecting the small bowel), it is recommended to perform an examination with three acquisitions (without injection, arterial time, and portal time). the department's experience has shown that arterial time is sometimes more sensitive than portal time for visualizing a parietal enhancement defect of the small bowel in mechanical occlusions. very few studies have investigated the diagnostic performance of parietal enhancement asymmetry on arterial time in mechanical occlusions of the small bowel.


Eligibility criteria:
inclusion criteria: * patient whose age is ≥ 18 years * patient with a diagnosis of mechanical small bowel obstruction on ct performed between april 2014 and december 2019 * patient who had a ct scan with at least 3 phases: injection-free, arterial time, portal time * french-speaking patient exclusion criteria: * patient who did not have surgery within the first 24 hours * patient with a history of abdomino-pelvic surgery in the month preceding the scan * patient under guardianship or curatorship * patient deprived of liberty * patient under court protection * patient who objects to the use of his or her data for this research
assessment of safety and efficacy of im19 for relapsed or refractory nhl patients

Conditions: Non Hodgkin Lymphoma

Summary: n this study, approximately 30 patients with relapsed or refractory non-hodgkin's lymphoma (nhl) were recruited for a single reinfusion of im19-cd28 and im19-41bb car-t cells. assess the safety, tolerability of treatment, and initially observe the efficacy.

1. dose-escalation:patients entered the im19-41bb or im19-cd28 group and performed dose escalation studies in three dose groups. 2. according to the results of the previous dose escalation study, select one dose to continue the enrollment of 6 patients for extended studies.

Eligibility criteria:
inclusion criteria: 1. relapsed or refractory cd19-positive non-hodgkin lymphoma (nhl) patients. 1 diffuse large b lymphoma (dlbcl), follicular lymphoma (fl), primary mediastinal b-cell lymphoma (pmbcl) patients meet one of the following conditions: i patients who have relapsed or are refractory after at least 2 previous treatments; ii patients who have relapsed after transplantation. 2 patients with relapsed or refractory mantle cell lymphoma after at least one treatment. 2. patients must have evaluable disease evidence; 3. age ≥ 18 years old; 4. the expected life span is more than 3 months; 5. ecog score 0-2 points (see attachment 2); 6. women of childbearing age have a negative blood pregnancy test before the start of the trial and agree to have effective contraceptive measures during the trial until the last follow-up; 7. those who voluntarily participate in the trial and sign the informed consent. exclusion criteria: 1. patients with high-risk organ involvement: tumors invade one of the central nervous system, gastrointestinal tract, lungs, pericardium, and large vessels; 2. those who have a graft-versus-host response and need to use immunosuppressive drugs; or who have a disease of the autoimmune system; 3. use chemotherapy or radiotherapy within 3 days before the blood collection period; 4. those who have used systemic steroids within the 5 days prior to the blood sampling period (except recently or currently using inhaled steroids); 5. use stimulating bone marrow hematopoietic cells to produce drugs (whitening needles, etc.) within 5 days before the blood collection period; 6. those who have previously used any gene therapy products; 7. history of epilepsy or other diseases of the central nervous system; 8. new york heart association (nyha) class iii or above (see annex 3); 9. creatinine\> 1.5 times the upper limit of normal or alt / ast\> 3 times the upper limit of normal or bilirubin\> 2 times the normal upper limit; 10. active hepatitis b or hepatitis c virus, hiv or other untreated active infections; 11. pregnant or lactating women; 12. suffer from other uncontrolled diseases that the researcher considers inappropriate; 13. any condition that the investigator believes may increase the subject's risk or interfere with the test results.

Keywords: car-t
percutaneous endocardial septal radiofrequency ablation in obstructive hypertrophic cardiomyopathy

Conditions: Obstructive Hypertrophic Cardiomyopathy

Summary: this prospective, multicenter, single-arm objective performance criteria trial is designed to assess the efficacy and safety of the percutaneous endocardial septal radiofrequency ablation (pesa) procedure in the treatment of obstructive hypertrophic cardiomyopathy (ohcm). the primary objectives include investigating: 1. the treatment efficacy and safety of pesa treatment in ohcm patients with either left ventricular outflow tract obstruction (lvoto) or midventricular obstruction; 2. the impact of pesa treatment on the functional capacity, quality of life and long-term prognosis of ohcm patients with either lvoto or midventricular obstruction.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of hypertrophic cardiomyopathy; * at least 18 years old; * the presence of a resting or maximum provoked lvot/midventricular gradient of ≥50 mmhg with symptoms, despite maximum tolerated medical therapy; * willing to receive pesa treatment; * lvef≥55%; * signed and dated written informed consent and willing to return for clinical follow-up. exclusion criteria: * midventricular obstruction rendered by isolated papillary muscle hypertrophy; * complete right bundle branch block; * acute decompensation heart failure with nyha iv; * previous septal reduction therapy including surgical and interventional procedures; * combination of other diseases requiring surgical treatment (including but not limited to coronary artery bypass grafting and apical aneurysm); * contraindications of radiofrequency ablation procedure; * women who are pregnant or lactating, or who plan to become pregnant while in the trial; * currently enrolled in another investigational device or drug trial; * combining any other clinical condition with a life expectancy less than 1 year.
cervicogenic headache dose-response

Conditions: Cervicogenic Headache

Summary: this study will determine the number of visits to a chiropractor for spinal manipulation and light massage necessary for the optimal relief of cervicogenic headache (headache with associated neck pain). effectiveness of care will also be determined.


Eligibility criteria:
inclusion criteria: * chronic cervicogenic headache * threshold pain level * threshold headache frequency * independently ambulatory * english literate * candidate for spinal manipulation exclusion criteria: * contraindication to thrust spinal manipulation or massage * most other headache types * recent manual/exercise therapy from licensed provider for head/neck * threshold pain medication use * pregnancy * involvement with another pain study * suspicion of unmanaged depression * most cancers * hypertension (at least stage ii) * complicating neurological/spinal conditions * pre-randomization noncompliance or cannot/will not comply with protocols * health-related litigation, claims, or disability compensation

Keywords: cervicogenic headache spinal manipulation chiropractic randomized controlled trial dose-response efficacy
pelvic imrt with tomotherapy in post-hysterectomy endometrial cancer patients

Conditions: Endometrial Cancer

Summary: this study is evaluating the feasibility of using helical tomotherapy to deliver imrt in post-hysterectomy endometrial cancer patients receiving adjuvant radiotherapy.


Eligibility criteria:
inclusion criteria: 1. age greater than or equal to 18 years of age 2. karnofsky performance status of greater than or equal to 60 3. figo surgical stage i, ii, and iii 4. pathologic confirmation of endometrial cancer 5. patient status post hysterectomy 6. patients with local or regional metastases are eligible for this protocol, but not those with distant metastases 7. patients must have adequate: * bone marrow function: * anc ≥ 1,500/mcl (\< ctcae v 3.0 grade 1). * platelets ≥ 100,000/mcl (\< ctcae v3.0 grade 1). * renal function: * serum creatinine ≤ institutional upper limit normal (uln) (ctcae v 3.0 grade 0). note: if serum creatinine \> uln, a 24-hour creatinine clearance must be collected and must be \> 50 ml/min. * hepatic function: * bilirubin ≤ 1.5 x uln (\< ctcae v 3.0 grade 1). * sgot≤ 2.5 x uln (\< ctcae v 3.0 grade 1). * alkaline phosphatase ≤ 2.5 x uln (\< ctcae v 3.0 grade 1). * neurologic function: * neuropathy (sensory and motor) \< ctcae v 3.0 grade 1. exclusion criteria: 1. age less than 18 years of age 2. karnofsky performance status less than 60 3. radiographic or pathologic evidence of metastatic disease (other than pelvic or para-aortic lymph nodes) 4. prior pelvic radiation therapy

Keywords: imrt tomotherapy post-hysterectomy endometrial cancer
the effect of anti-epileptic drugs on mitochondrial activity

Conditions: Epilepsy

Summary: this study is based on the hypothesis that antiepileptic drugs (other than valproic acid) have an effect on the mitochondrial oxidative phosphorylation. the objective of this study is to evaluate this effect in an accessible tissue-human peripheral white blood cells.

antiepileptic drugs adverse reactions, including hepatotoxicity, are rare but potentially fatal, especially among children. although the mechanism of the liver toxicity remains elusive, mitochondrial oxidative stress, has been hypothesized to play a role. most of the studies addressing antiepileptic drug effects on the mitochondria discuss the effect of valproic acid. the exact mechanisms involved in the drug-induced effects on oxidative phosphorylation are still far from being resolved. most of the studies investigated the effect of valproic acid by using animal models or different in vitro methods.mitochondrial diseases should be considered as a risk factor for valproic acid-induced hepatotoxicity, and there is a consensus for avoiding the administration of the drug for these patientsis it possible that other antiepileptic drugs have similar effects? the knowledge regarding the effects of other antiepileptic drugs on the mitochondria is relatively scarce.

Eligibility criteria:
inclusion criteria: * children between the ages of 3 and 18 years old, who suffer from new onset epilepsy as diagnosed by a certified pediatric neurologist, who do not suffer from a ''metabolic'' disorder, are treated by a single antiepileptic drug, and are not receiving any other type of medication on a chronic basis were included exclusion criteria: * children younger than 3 years of age or older than 18 years of age, children who were suspected or known to suffer from a ''metabolic'' disorder or liver dysfunction, children who were under treatment, by any medication on a chronic basis, at the time of the study were excluded.

Keywords: antiepileptic drugs mitochondria
a local clinical study for the comparative evaluation of efficacy and safety of angal, lozenges [menthol] and anti-angin® formula, lozenges, in treatment of patients with a sore throat

Conditions: Sore Throat

Summary: the purpose of this study was to evaluate no less therapeutic efficacy and safety of the angal, lozenges \[menthol\], 1 mg + 5 mg (sandoz dd, slovenia) compared to anti-angin® formula, lozenges, 0,2 mg + 2 mg + 50 mg (llc "valeant", russia) in treatment of patients with uncomplicated acute infectious and inflammatory diseases of the pharynx, accompanied by a sore throat.


Eligibility criteria:
inclusion criteria: * voluntarily signed informed consent for participation in this clinical study; 18 to 45 years old inclusive, male and female; * diagnosed uncomplicated acute infectious and inflammatory diseases of the pharynx, accompanied by a sore throat; * onset of first symptoms of the uncomplicated acute infectious and inflammatory diseases of the pharynx (pharyngitis and/or tonsillitis) less than 48 hours prior to inclusion into the study; * baseline tss score (tonsillopharyngitis severity score) ≥ 5 (total score); exclusion criteria: * use of analgesics within \<12 hours prior to the study start or/and inability to cancel them during the study; * use of antibiotics within \<48 hours prior to the study start or/and inability to cancel them during the study; * use of local therapy (sprays, rinses, lozenges) to pharynx within \<12 hours before study start or/and inability to cancel them, besides study medications. * use systemic or inhaled corticosteroids within ≤1 months prior to the study start and planned therapy of them during the study (besides skin means). * presence of symptoms of primary bacterial pharyngitis or secondary bacterial infection (including fever over 37,5 ° c, the presence of purulent raids in the throat, severe intoxication, leukocytosis, neutrophilia, shift leukocyte left (increasing the percentage of neutrophils sticks appearance younger forms of neutrophils), increased esr 30 mm/hr);

Keywords: angal anti-angin® formula sore throat no less therapeutic efficacy
family peer navigator for early psychosis for black families

Conditions: Family Members

Summary: building upon formative research, this mixed methods study will be conducted in three phases to develop, refine, and pilot-test a multi-component family peer navigator model designed to increase access to and initial engagement in coordinated specialty care for early psychosis among black/african american families.

the overall goal of this mixed methods study will be conducted in three phases to develop, refine, and pilot-test a multi-component family peer navigator model designed to increase access to and engagement in coordinated specialty care programs among black/african american families. phase ii will recruit 10 family member participants to complete a four-month open trial to refine the family peer navigator model. during phase iii, a total of 40 black/african american families will be recruited to participate in a randomized pilot trial of the family peer navigator model against a low-intensive care coordination in two coordinated specialty care programs to assess acceptability, feasibility, and preliminary impact.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age 2. identifies as black/african american 3. loved one who meets criteria for risk of psychosis with a total score of ≥ 3 on the prodromal questionnaire- brief version exclusion criteria: 1. family members who cannot understand the consent process 2. non-english speaking adults 3. black/african american families referred to coordinated specialty care and who have already been determined eligible for services by providers.

Keywords: black/african american early psychosis access and engagement
effect of increasing testosterone on insulin sensitivity in men with the metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the purpose of the study is to examine the effect of testosterone treatment on insulin in men with the metabolic syndrome with testosterone levels at or below the lower end of the normal range.

the metabolic syndrome is a medical condition defined by high cholesterol levels, high blood pressure, increased abdominal obesity (gain in fat around the region of the stomach), and insulin resistance. insulin is the hormone that your body produces to decrease the levels of sugar in your blood. a person that is insulin resistant needs more insulin to decrease blood sugar levels than a normal person does. insulin resistance can lead to type 2 diabetes, which is one of the most common illnesses in the united states. there is evidence pointing to a relationship between insulin and testosterone in men (testosterone is the male sex hormone that is produced in the testes). as men get older their testosterone levels decrease while their weight and insulin resistance tends to increase. the purpose of this research study is to learn more about the details of the relationship between insulin and testosterone. a clearer understanding of this relationship can have an important impact on public health due to the high rate of health problems associated with diabetes, obesity, and heart disease. we are looking for men between the ages of 50-75 with the metabolic syndrome to participate in this research study. participation in this study involves taking medication and/or placebo (a placebo looks exactly like the study medication but contains no active drug), blood tests, muscle biopsies, and imaging scans. this study involves outpatient visits. subjects are paid up to $500 for completing the study.

Eligibility criteria:
inclusion criteria: stable weight for previous three months (no weight change greater than or equal to +/-10 lbs) exclusion criteria: * no new diagnosis of type 2 diabetes or on oral hypoglycemic agents * no history of testicular disorders * no history of bleeding disorders (i.e. pulmonary embolism, deep vein thrombosis, stroke, hypercoagulable syndrome) * no history of prostate cancer * no previous diagnosis of osteoporosis * no history of sleep apnea (subjects will also be excluded if at their baseline assessment they admit to heavy snoring, restless sleep, and/or excessive daytime somnolence) * no symptoms of urinary outflow obstruction or medications for prostate disease * no illicit drug use or heavy alcohol use (\>4 drinks/day)

Keywords: overweight obesity testosterone diabetes metabolic syndrome aging
correlation between pupil size and ocular signs of pseudoexfoliation syndrome

Conditions: Pseudoexfoliation Syndrome; Pseudoexfoliation Glaucoma in Both Eyes; Pseudoexfoliation of Lens; Glaucoma

Summary: to study possible correlation between the size of the pupil in both room light and after dilation between both eyes in bilateral pseudoexfoliation with intraocular pressure, lens clarity and stability, optic disc , visual changes and glaucoma changes by optical coherence tomography

for each patient. full preoperative ophthalmological assessment will be done using slit lamp , size of the pupil in regular room light (usually around 2000 lux) and post dilation with tropicamide 1%. baseline iop measurement using goldmann applanation tonometer, ucdva (uncorrected distance visual acuity)and cdva (corrected distance visual acuity), lens opacification or clarity, stability or subluxation. corneal endothelial cell count. fundus examination using 90 d or 78d lenses, humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (rnfl) and ganglion cell complex.(gcc)

Eligibility criteria:
inclusion criteria: all patients with pseudoexfoliation syndrome exclusion criteria: previous ocular surgery or ocular trauma affecting pupil. any systemic or neurologic disease affecting pupil

Keywords: cataract glaucoma
the effects of sedatives on tobacco use disorder

Conditions: Tobacco Use Disorder

Summary: this proposal will obtain preliminary data on the effect of a single sub-anesthetic dose of a sedative on cigarette craving and smoking behavior as well as measuring tolerability and acceptability.


Eligibility criteria:
inclusion criteria: * smoke at least 5 cigarettes per day * smoked at least 2 years * negative urine drug screen for psychoactive drugs and negative breath alcohol concentration * live in little rock ar or surrounding area exclusion criteria: * unstable or stable medical condition that would interact with study medication or participation * serious head trauma or neurological disorder * hypertension, abnormal ecg or metabolic blood results * meet criteria for psychosis, schizophrenia, major depressive disorder, or bipolar disorder * use of psychoactive drugs or medications * bmi \> 40 * among women, pregnancy or breastfeeding
the first twenty for volunteer firefighters

Conditions: Obesity; Cardiovascular Diseases; Occupational Injuries

Summary: the purpose of this study is to assess the efficacy of an internet-based firefighter health and wellness program for volunteer fire departments.

a national sample of volunteer fire departments will be recruited for a 6 month, crct with a cross-over treatment design to determine the efficacy of the first twenty (tf20), a wellness program focused on nutrition and fitness for firefighters. modifications to the existing tf20 will be made to enhance the health coaching features and include tools for program evaluation. study outcomes (changes in weight, bmi, body fat percentage, waist circumference, dietary intakes, blood pressure, and fitness activities) will be assessed pre- and post-intervention. this will be the first internet-based, occupationally tailored health and wellness program implemented for the volunteer fire service. tf20 will be an essential cost effective tool to address the epidemic of unhealthy body composition, nutrition and fitness among firefighters.

Eligibility criteria:
inclusion criteria: * first responder within a participating fire department * willing to complete all assessments * internet accessibility through a computer, tablet or smartphone and ability to use devices appropriately exclusion criteria: - not a first responder within a participating fire department

Keywords: nutrition fitness cardiovascular disease firefighters obesity injury